
Please try another search
After-Hours Stock Movers:
Chewy (NYSE:CHWY) 8% LOWER; reported Q2 net income of $22.3 million. Revenue for the quarter came in at $2.43 billion versus the consensus estimate of $2.45 billion.
Ambarella (NASDAQ:AMBA) 5% LOWER; reported Q2 EPS of $0.20, $0.01 better than the analyst estimate of $0.19. Revenue for the quarter came in at $80.9 million versus the consensus estimate of $80.19 million. Ambarella sees Q3 2023 revenue of $81-85 million, versus the consensus of $85 million.
PVH Corp. (NYSE:PVH) 4% LOWER; reported Q2 EPS of $2.08, $0.08 better than the analyst estimate of $2.00. Revenue for the quarter came in at $2.13 billion versus the consensus estimate of $2.21 billion. PVH Corp. sees FY2022 EPS of $8.00, versus the consensus of $8.68.
HP Inc. (NYSE:HPQ) 4% LOWER; reported Q3 EPS of $1.04, in-line with the analyst estimate of $1.04. Revenue for the quarter came in at $14.7 billion versus the consensus estimate of $15.69 billion. HP Inc. sees Q4 2022 EPS of $0.79-$0.89, versus the consensus of $1.06. HP Inc. sees FY2022 EPS of $4.02-$4.12, versus the consensus of $4.30.
Chargepoint Holdings Inc. (CHPT) 2% HIGHER; reported Q2 EPS of ($0.28), $0.06 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $108 million versus the consensus estimate of $103.01 million. Chargepoint Holdings Inc. sees Q3 2023 revenue of $125-135 million, versus the consensus of $130 million. Chargepoint Holdings Inc. sees FY2023 revenue of $450-500 million, versus the consensus of $476.5 million.
Hewlett Packard Enterprise (NYSE:HPE) 1% HIGHER; reported Q3 EPS of $0.48, $0.01 better than the analyst estimate of $0.47. Revenue for the quarter came in at $7 billion versus the consensus estimate of $6.93 billion. Hewlett Packard Enterprise sees Q4 2022 EPS of $0.52-$0.60, versus the consensus of $0.58. Hewlett Packard Enterprise sees FY2022 EPS of $1.96-$2.04, versus the consensus of $2.03. Reiterates fiscal 2022 revenue growth of 3-4% adjusted for currency.
Amgen (NASDAQ:AMGN) 1% HIGHER; announced that the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS® (sotorasib) met its primary endpoint of progression-free survival (PFS), demonstrating statistical significance and superiority over standard of care chemotherapy, intravenous docetaxel. The first randomized clinical trial for a KRASG12C inhibitor assessed the efficacy and safety of LUMAKRAS in 345 previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) who had received at minimum, prior platinum-based doublet chemotherapy and checkpoint inhibitor therapy.
CrowdStrike Holdings Inc. (NASDAQ:CRWD) 1% LOWER; reported Q2 EPS of $0.36, $0.08 better than the analyst estimate of $0.28. Revenue for the quarter came in at $535.2 million versus the consensus estimate of $515.98 million. CrowdStrike Holdings Inc. sees Q3 2023 EPS of $0.30-$0.32, versus the consensus of $0.28. CrowdStrike Holdings Inc. sees Q3 2023 revenue of $569.1-575.9 million, versus the consensus of $568.6 million. CrowdStrike Holdings Inc. sees FY2023 EPS of $1.31-$1.33, versus the consensus of $1.20. CrowdStrike Holdings Inc. sees FY2023 revenue of $2.223-2.232 billion, versus the consensus of $2.2 billion.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.